Cytokinetics, Inc. is a leading pharmaceutical company in the United States that focuses on developing treatments for diseases affecting muscle function. Specializing in ESG-driven solutions, Cytokinetics creates innovative treatments for conditions like amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. With a medium risk rating score of 21.5, Cytokinetics is dedicated to improving the health span of individuals with cardiovascular and neuromuscular diseases.